| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1657 | |
| Phytochemical name or plant extracts | Pseurotin A | |
| PMID | 32438039 | |
| Literature evidence | Surface plasmon resonance (SPR) showed PS ability to inhibit the PCSK9-LDLR interaction at a concentration range of 10-150 μM. | |
| IUPAC name | (5S,8S,9R)-8-benzoyl-2-[(Z,1S,2S)-1,2-dihydroxyhex-3-enyl]-9-hydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione | |
| Phytochemicals’ class or type of plant extracts | spirocyclic | |
| Source of phytochemicals or plant Extracts | Aspergillus fumigatus | |
| Geographical availability | NA | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | PCSK9 | |
| Gene or Protein evidence | PS treatment significantly reduced PCSK9 expression and normalized LDLR levels in collected primary and recurrent breast tumors at the study end. | |
| Target pathways | NA | |
| IC50 | At 24h, 48h, 72h: 260.83 μM, 98.88 μM, 93.64 μM against BT-474 respectively 260.83 μM, 120.92 μM, 113.08 μM against T47D respectively | |
| Potency | PS is a novel first-in-class PCSK9-targeting lead appropriate for the use to control hormone-dependent BC progression and recurrence. | |
| Cell line/ mice model | BT-474, T47D | |
| Additional information | The results of this study provide the first evidence for the suppression of the hormone-dependent breast tumor progression and recurrence by targeting the PCSK9-LDLR axis. | |
| PubChem ID | 9845622 | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |